Ilan Cohn, Ph.D.
Dr. Ilan Cohn is a co-founder of the company and its Chairman. Dr. Cohn is a senior partner of Reinhold Cohn & Partners the largest IP firm in Israel. He manages the life sciences and chemistry department of Reinhold Cohn, which includes a very large staff of patent attorneys, trainees, paralegals, and assistant staff. Dr. Cohn, has many years of experience in the field of patents and other intellectual property fields. Additionally, in the course of his professional career Ilan gained significant experience and expertise in turning intellectual property assets, particularly patents into a first tier asset. He holds a Ph.D. in biology. He served on the board of directors of a number of life science companies in Israel and in the USA. He was also involved in the past in management of VC funds focused on investment in the field of the life sciences. Dr. Cohn served a number of years as a co-chairman of the Biotech Committee of the US-Israeli Science and Technology Commission.
Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Prof. Fishman is the scientific founder of the company and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is a very accomplished scientist and has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built. This scientific work has gained recognition as one of the leading approaches for new generation therapies for cancer and other diseases. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of the commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. She was also involved in the establishment and served on the Board of Directors of several life sciences technology start-ups.
During the past 35 years, Mr. Yossi Bornstein has played key roles in the Israeli biomed industry. He was the General Manager of Bristol-Myers Squibb (Israel). Mr. Bornstein is the CEO and the founder of Shizim group, a life science holding company. He is the Founder of ShizimXL, International Medical Devices & ShizimVS, Digital Health innovation centers. He is the Chairman of GCP Clinical Studies Ltd., one of the top providers of clinical research services and educational programs in Israel. He served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (the “USISTC”). Mr. Bornstein is the founder of ILSI - Israel Life Science Industry Organization and Founder of ITTN - Israel Tech Transfer Organization. He is a Co-Founder and director of Microbot Medical (NASDAQ: MBOT) and a Director of XACT Robotics.
Yaacov Goldman has served as external director since August 2017. Mr. Goldman provides consulting services to companies in strategic-financial areas, through his wholly owned company, Maanit-Goldman Management & Investments (2002) Ltd. Mr. Goldman also serves as a director of Avgol Industries 1953 Ltd., Meitav Dash Investments Ltd., Industrial Buildings Corporation Ltd., IceCure Medical Ltd. and Fattal Properties (Europe) Ltd. Mr. Goldman served as the Professional Secretary of the Peer Review Institute of the Certified Public Accountants Institute in Israel from October 2004 until September 2008. Commencing in 1981, Mr. Goldman worked for Kesselman & Kesselman (Israeli member firm of PricewaterhouseCoopers) for 19 years, and from 1991 until 2000, as a partner and then senior partner of such firm. From September 2000 until November 2001, Mr. Goldman served as managing director of Argoquest Holdings, LLC. Mr. Goldman holds a B.A. degree in Economics and Accounting from Tel Aviv University and is a Certified Public Accountant (Israel).
Mr. Guy Regev is currently the Chief Executive Officer of Shaked Global Group, a privately-held equity investment firm that provides value added capital to environmental related companies and technologies. Shaked Global Group is a major shareholder in Can-Fite BioPharma and Mr. Regev is a director of Can-Fite. Mr. Regev has over 12 years of experience in accounting, financial management and control and general management of commercial enterprises. Prior to joining Shaked, Mr. Regev was Vice President, commercial business, at Housing & Construction Holding (HCH), Israel's largest infrastructure company. Between 1999 and 2001, Mr. Regev was a manager at Deloitte & Touche, Israel.
Abraham Sartani, MD.
Dr. Sartani was till recently a Vice-President and Director Pharmaceutical Research and Development Division, of Recordati. Prior to joining Recordati in 1985, Dr. Sartani was in Farmitalia-carlo Erba since 1980, serving in an number of roles including the Medical Director for Europe. He is a member of a number of scientific and management societies and the author/co-author of numerous publications and patents.